Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCUL101 in Neovascular Age-Related Macular Degeneration (STAT)
NCT07520318Phase 3Not yet recruiting
- Sponsor
- Oculgen Biomedical
- Start
- Apr 2026
- Primary completion
- Feb 2029
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
A Phase 3 trial of OCUL101 in neovascular age-related macular degeneration (NVAMD), sponsored by Oculgen Biomedical. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
OCUL101
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT07520318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07520318.